Health
Study shows reliability and robustness of injectable anti-obesity medication – News-Medical.Net
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing…
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the Journal of the American Medical Association.
The 68-week study was conducted at 41 sites in the…
-
Business18 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News17 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Business13 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News16 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses